127 related articles for article (PubMed ID: 18237441)
1. Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial.
Rajendram R; Lee RW; Potts MJ; Rose GE; Jain R; Olver JM; Bremner F; Hurel S; Cook A; Gattamaneni R; Tomlinson M; Plowman N; Bunce C; Hollinghurst SP; Kingston L; Jackson S; Dick AD; Rumsey N; Morris OC; Dayan CM; Uddin JM
Trials; 2008 Jan; 9():6. PubMed ID: 18237441
[TBL] [Abstract][Full Text] [Related]
2. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
Rajendram R; Taylor PN; Wilson VJ; Harris N; Morris OC; Tomlinson M; Yarrow S; Garrott H; Herbert HM; Dick AD; Cook A; Gattamaneni R; Jain R; Olver J; Hurel SJ; Bremner F; Drummond SR; Kemp E; Ritchie DM; Rumsey N; Morris D; Lane C; Palaniappan N; Li C; Pell J; Hills R; Ezra DG; Potts MJ; Jackson S; Rose GE; Plowman N; Bunce C; Uddin JM; Lee RWJ; Dayan CM
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):299-309. PubMed ID: 29396245
[TBL] [Abstract][Full Text] [Related]
3. Orbital radiotherapy for adult thyroid eye disease.
Rajendram R; Bunce C; Lee RW; Morley AM
Cochrane Database Syst Rev; 2012 Jul; (7):CD007114. PubMed ID: 22786503
[TBL] [Abstract][Full Text] [Related]
4. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
[TBL] [Abstract][Full Text] [Related]
5. Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.
Taylor P; Rajendram R; Hanna S; Wilson V; Pell J; Li C; Cook A; Gattamaneni R; Plowman N; Jackson S; Hills R; French R; Uddin JM; Lee RWJ; Dayan CM
J Clin Endocrinol Metab; 2023 Sep; 108(10):2615-2625. PubMed ID: 36971324
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
7. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
8. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial.
Jayarajah U; Wijekoon M; Seneviratne SA
Trials; 2020 Sep; 21(1):812. PubMed ID: 32993815
[TBL] [Abstract][Full Text] [Related]
10. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease.
Claridge KG; Ghabrial R; Davis G; Tomlinson M; Goodman S; Harrad RA; Potts MJ
Eye (Lond); 1997; 11 ( Pt 5)():717-22. PubMed ID: 9474324
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Surgical orbital decompression for thyroid eye disease.
Boboridis KG; Bunce C
Cochrane Database Syst Rev; 2011 Dec; (12):CD007630. PubMed ID: 22161415
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience.
Chalvatzis NT; Tzamalis AK; Kalantzis GK; El-Hindy N; Dimitrakos SA; Potts MJ
Eur J Ophthalmol; 2014; 24(6):953-9. PubMed ID: 24706350
[TBL] [Abstract][Full Text] [Related]
14. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.
Webb NJA; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Deeks JJ; Wheatley K; Ives NJ;
BMJ; 2019 May; 365():l1800. PubMed ID: 31335316
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
[TBL] [Abstract][Full Text] [Related]
16. A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.
Droitcourt C; Barbarot S; Maruani A; Darrieux L; Misery L; Brenaut E; Adamski H; Chabbert C; Vermersch A; Weiborn M; Seneschal J; Taïeb A; Plantin P; Maillard H; Phan A; Skowron F; Viguier M; Staumont-Salle D; Nosbaum A; Soria A; Barbaud A; Oger E; Dupuy A;
Trials; 2019 Mar; 20(1):184. PubMed ID: 30909923
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
18. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[TBL] [Abstract][Full Text] [Related]
19. A phase III, multi-centre, double-masked randomised controlled trial of adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): statistical analysis plan.
Lo JW; Bunce C; Charteris D; Banerjee P; Phillips R; Cornelius VR
Trials; 2016 Aug; 17():383. PubMed ID: 27484082
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
